Introduction to Psychedelics and Reimbursement

Why approval is not the same as access

How psychedelic therapy got here

Psychedelic substances have long histories in Indigenous, religious, spiritual, and healing contexts. Modern medical research later studied compounds such as LSD, psilocybin, MDMA, ketamine, and esketamine for mental-health conditions. The access question today is not only whether these treatments can work, but whether health systems can regulate, fund, and deliver them responsibly.

Western medical research expanded in the mid-20th century, especially around LSD and psilocybin. That early period produced clinical interest, but many studies would not meet current trial standards.

Research slowed after tighter drug controls, political backlash, and stricter regulatory expectations. The modern field now has to rebuild evidence under today's safety, trial, and reimbursement standards.

That gap still matters. Modern developers cannot rely on early interest alone; they need contemporary evidence on safety, efficacy, durability, service delivery, and value for money.

Modern resurgence

Modern research interest grew again in the early 21st century, helped by neuroscience, new trial infrastructure, and frustration with existing mental-health options.[5]1 Researchers began to revisit earlier findings and test whether psychedelic effects could be studied under modern clinical standards.

Johns Hopkins University and Imperial College London helped restart modern clinical research. The 2006 Johns Hopkins psilocybin study showed that a major institution could study psilocybin under contemporary safety and ethics standards, which helped open the door to later patient trials.

Regulators have also started to use accelerated-development tools in this field. In 2017, FDA granted Breakthrough Therapy designation to MDMA therapy for PTSD. The designation is meant for drugs that may improve substantially on existing options, but it does not guarantee approval or reimbursement.

The FDA later granted Breakthrough Therapy designations to several psychedelic programmes, including Compass Pathways' psilocybin therapy for treatment-resistant depression, Usona Institute's psilocybin therapy for major depressive disorder, Cybin's CYB003 programme for MDD, and MindMed's MM120 programme for generalised anxiety disorder. These designations can speed development conversations, but they do not prove value or secure coverage.

UK regulators have used the Innovative Licensing and Access Pathway for several psychedelic programs, including COMPASS Pathways' psilocybin therapy, MAPS/Lykos MDMA therapy, and MindMed's MM120 program. The pathway can create earlier regulator engagement, but access still depends on later evidence and payment decisions.

EMA has also engaged with psychedelic medicines, including a two-day workshop on regulatory and clinical-development questions. PRIME could support medicines for unmet need, but no psychedelic therapy has yet received PRIME designation.

Why the support model matters

Many psychedelic therapy models combine a medicine with psychological support. The amount and type of support remain debated and may differ by compound, indication, patient risk, and reimbursement route. That debate matters because support time is part of what health systems may have to pay for.

Trial teams often describe different mechanisms for different compounds. MDMA therapy for PTSD may reduce fear and defensiveness during trauma processing, while psilocybin therapy may affect connectedness, perspective, and depressive symptoms (Mitchell et al., 2021; Davis et al., 2021).

The reimbursement issue is practical: if psychological support contributes to safety or effect, someone has to train staff, schedule rooms, pay for time, and decide which parts of the model are essential.

What a typical protocol includes

Many protocols use three phases (Brennan & Belser, 2022):

1. Preparation: one or more sessions to explain the treatment, screen risks, build trust, and prepare the patient for the dosing day.

1. Dosing session: the patient receives the medicine in a controlled setting under professional supervision. Depending on the compound, sessions can last from about one hour to most of a day, with staff available to monitor safety and provide support.[6]

1. Integration: follow-up sessions help patients reflect on the experience and connect it to practical changes in behaviour, relationships, symptoms, or coping.

Set and setting are part of the safety model

In psychedelic care, "set and setting" refer to the patient's mindset and the treatment environment (Hartogsohn, 2017):

• Set: the patient's expectations, mood, intentions, fears, and trust in the team.

• Setting: the physical room, supervision, social context, safety procedures, and sense of control during the session.

Healthcare practitioners help manage set and setting by preparing patients, shaping the treatment environment, and responding to distress during care.[7]2

Rapid and sustained symptom reduction

Psychedelic therapies may produce symptom improvement after one or a few dosing sessions, while many conventional antidepressants require weeks of daily use before therapeutic effects appear. Response still varies, and trial results do not guarantee durable benefit for every patient (Bahji et al., 2023).

In Compass Pathways' Phase IIb trial in treatment-resistant depression, a single 25 mg psilocybin dose with psychological support reduced depressive symptoms more than lower doses in some participants within days. Among responders, some benefits lasted up to 12 weeks (Goodwin et al., 2022). For access planning, the key question is how often those gains persist and what follow-up support is needed.

Emerging evidence across mental health conditions

The strongest access case is often in patients who have not responded to existing options. Treatment-resistant depression, chronic PTSD, and substance-use disorders create a clear unmet-need argument, but payers still need evidence that benefits are durable, safe, and worth the full service cost (Howes et al., 2022; McIntyre et al., 2023).

MDMA-assisted therapy trials in PTSD reported large symptom improvements compared with placebo-supported therapy (Mitchell et al., 2021; Mitchell et al., 2023). Those results helped establish clinical interest, while also raising access questions about therapist time, protocol fidelity, safety monitoring, and which patients should qualify.

Research is also expanding beyond TRD and PTSD into substance-use disorders, anxiety related to terminal illness, eating disorders, obsessive-compulsive disorder, and other mental-health conditions. The access question will differ by indication because comparators, patient populations, service costs, and payer priorities differ.[8]3

Psychedelic therapies differ from ordinary prescribing because the clinical model often includes preparation, a supported psychoactive experience, monitoring, and integration. That means access depends on more than product approval. Health systems also need trained staff, suitable settings, payment for non-drug care, and rules for follow-up.

This section explains why reimbursement may be difficult even when trial results are positive. It focuses on four questions: what blocks access, which groups shape adoption, which reimbursement pathways are plausible, and what service-design problems need to be solved before patients can receive care.

Current reimbursement landscape in Europe

In Europe, marketing authorisation is only one step. After EMA approval, each country decides whether to fund the treatment, at what price, for which patients, and through which providers. The UK and Switzerland make separate authorisation and reimbursement decisions.

At present, legal medical access is concentrated around esketamine and ketamine-related care. Spravato has regulatory approval for treatment-resistant depression, but reimbursement and practical availability differ by country. Ketamine is used off label or through specific clinical settings, often with private payment or case-by-case arrangements. Most other psychedelic therapies remain limited to trials.

Why national systems create different access paths

European countries generally aim for universal coverage, but they organise payment and decision-making differently. Those differences shape how quickly new treatments become available and whether patients face out-of-pocket costs.

Healthcare models

Tax-funded public systems, such as the NHS in the UK, often make national decisions about which treatments are funded. A positive decision can support broad access, while a negative decision can block routine public coverage.

Insurance-based systems, such as Germany and the Netherlands, rely on mandatory health insurance with national rules and payer involvement. They may offer more than one reimbursement route, but they still need clear evidence, pricing, and delivery arrangements.

Mixed systems combine public funding with private delivery or regional responsibility. This can create earlier local adoption in some places and uneven access in others.

Decision making

Decision-making also differs in how centralised it is (Montagu, 2021). England and Wales, and the Netherlands, rely heavily on national bodies. A single recommendation can therefore affect access across much of the system.

Spain and Italy give regions more power over funding and delivery decisions. Germany combines national benefit assessment with statutory and private insurance arrangements, optional benefits, and contract-based care models.

Timing for access

Access timelines vary widely across Europe (EFPIA, 2022; EFPIA, 2024a). Germany is fastest in the EFPIA dataset, with new treatments available on average 126 days after approval when manufacturers enter immediately. Denmark and Austria follow at 149 and 283 days; the Netherlands averages 371 days and the Czech Republic 494 days. Bulgaria, Romania, and Poland take much longer. Speed is only part of the access question: in some countries, only a small share of EMA-approved treatments becomes available at all.

Private healthcare options

Private care can fill gaps when public systems move slowly or decline coverage, but it creates a different access problem. Patients may get faster treatment if they can pay, while others wait or go without.

This raises equity concerns. Ketamine care already shows the risk: treatment is often available through private clinics that require large out-of-pocket payments. If psychedelic therapies follow that model, lower-income patients and groups with higher mental-health burden may be excluded.

What this means for psychedelic therapies

Europe's different healthcare systems create access problems for psychedelic therapies. These treatments combine a medicine with psychological support, while many systems evaluate medicines and therapy services through separate routes. Countries may therefore reach different answers about reimbursement, provider payment, and patient eligibility.

If private clinics become the main route, access will likely favour patients with money, proximity, and health literacy. Public reimbursement is therefore not only a financing issue; it is central to whether access is equitable.

Status of psychedelic therapies across key markets

The main legal medical examples discussed here are esketamine, which has regulatory approval for treatment-resistant depression, and ketamine, which is used in selected hospital settings and private clinics. Approval does not guarantee payer acceptance, as shown by the varied reimbursement status and practical availability of these treatments across Europe. The country summaries below use those examples to show how access can diverge.

Germany

Germany illustrates how approval, benefit assessment, and delivery capacity interact. G-BA recognised a considerable added benefit for Spravato in treatment-resistant depression when used with an SSRI or SNRI (G-BA, 2023). Public insurance can cover eligible treatment, but practical access still depends on specialised sites and prescriber willingness.

Beyond Spravato, off-label ketamine is used in a limited number of clinics, often through private payment or case-by-case insurance approval. Germany permits access to esketamine and ketamine therapies, but practical delivery is constrained by specialised-site availability and prescriber willingness. Research initiatives, including EPIsoDE in treatment-resistant depression and related later-stage planning, show scientific activity without creating routine access on their own.

Netherlands

The Netherlands has more practical ketamine-related care than many European countries, but coverage is partial and fragmented. Psychotherapeutic components may be easier to fund than drug costs, which shows how access can improve without full reimbursement being solved.

Spravato was approved for coverage under basic health insurance in 2021, but use remained limited. Reports estimated 1,500-2,000 eligible TRD patients annually, while only a few dozen received treatment in 2022 (ZiN, 2020; Depressie Vereniging, 2022).

Some hospital systems offer off-label ketamine case by case. Dutch researchers have also worked toward trials that could support broader coverage by giving payers stronger evidence on efficacy, safety, and delivery.

Psilocybin access in the Netherlands sits mostly outside standard medical reimbursement. Some practitioners operate in unregulated or semi-regulated settings, while medical centres focus on approved treatments and research. That distinction matters for safety, evidence, and payment.

In 2024, the Dutch State Commission on MDMA recommended a regulated medical route for MDMA therapy for PTSD (Government of the Netherlands, 2024). That recommendation supports policy discussion but does not by itself create reimbursed access.

United Kingdom

In England and Wales, NICE has not recommended Spravato for routine NHS use because of cost-effectiveness concerns (NICE, 2024a). Scotland reached a different conclusion through the Scottish Medicines Consortium, showing how access can diverge within the UK.

Ketamine access in the UK remains limited. A small number of NHS services and private clinics offer treatment, and pilots continue to test more replicable care models. Private access can be faster, but cost remains a major barrier (Oxford Health NHS Foundation Trust, 2024; Imperial College London, 2025).

The UK has several research-support channels. ILAP designations and public funding support psychedelic development and trials, including work in alcohol-use disorder, opioid addiction, gambling disorder, and depression-related indications. Research support, however, still has to translate into NHS coverage.

The main UK access hurdle is still economic. New psychedelic therapies will need evidence that meets NICE's cost-effectiveness expectations, including service costs and the uncertainty around durability.

Czech Republic

The Czech Republic offers one of Europe's more developed examples of ketamine therapy in clinical practice. A limited number of clinics provide treatment, some insurance coverage exists, and patients may still face substantial co-payment.

Since 2020, Czech clinics have treated hundreds of patients with ketamine therapy (Senk, 2023; Senk, 2024). Services have expanded beyond TRD into eating disorders, PTSD, addictions, and anxiety disorders, while research sites participate in studies of ketamine, 5-MeO-DMT, and psilocybin.

Czechia has insurance coverage agreements with major providers, including VZP, the country's largest insurer. Spravato (esketamine) is listed among reimbursed medicinal products by the State Institute for Drug Control (SÚKL, 2024), which supports public health insurance coverage for treatment-resistant depression.

Czech reimbursement is strongest where the product is formally listed. Spravato appears among SÚKL-reimbursed medicinal products, supporting public insurance coverage for treatment-resistant depression (SÚKL, 2024).

Other European markets

Switzerland stands out for exceptional-authorisation routes that allow limited medical access to MDMA, psilocybin, and LSD in specialised settings. That model shows how access can exist before broad reimbursement, but it remains limited and clinician-dependent (Liechti, 2019).

In most other European markets, access to Spravato or ketamine-related care remains hospital-based, private, or restricted by local coverage rules.

Early access and alternative pathways

Standard reimbursement through national health systems is the assumed route to broad access, but alternative routes already provide limited psychedelic or ketamine-related access in Europe.[9] These pathways show how implementation can begin before full national coverage, while also exposing problems around quality, cost, equity, and evidence.[9]4 These pathways offer important insights into implementation challenges and opportunities while generating valuable real-world evidence.

Compassionate use programs

Compassionate-use and exceptional-access routes can help patients with few remaining options, but they are not substitutes for routine reimbursement. They tend to be narrow, administratively heavy, and dependent on clinician capacity.

Research-based access

Clinical trials and research programmes remain an access route for some patients. They generate evidence, train teams, and create sites with practical protocol experience. Those pockets of expertise may later support broader implementation if reimbursement and governance routes develop.

Private clinic models

Private clinics are important early implementers, especially in ketamine care. They show what delivery requires in practice, but self-pay models also reveal the equity problem: practical access can exist while reimbursed access does not.

Off-label and pharmacy preparation

Off-label prescribing and pharmacy preparation can create flexible routes for ketamine in some countries. These routes may help clinicians treat selected patients, but coverage is often uncertain and evidence collection is uneven.

What this means for Road to Access

The reimbursement question starts with a simple distinction: approval can make a medicine legal, but access depends on payment, service design, trained staff, and patient selection. Psychedelic therapies make that distinction harder because the surrounding care is part of the intervention.

Use the rest of this section to move from the general access problem into the specific decisions that determine whether therapies can be funded and delivered in real systems: clinical evidence, HTA, country reimbursement, workforce, equity, and alternative access pathways.